ChosenMed recently closed a Series C1 financing, raising several hundred million RMB from Yijing Capital, with participation from Gaoxin Health Care and Jingming Capital.

CEC Capital served as the exclusive financial advisor to ChosenMed in this transaction.

The proceeds from this financing will primarily be used to advance the clinical registration of its products for the diagnosis of lung cancer and gastrointestinal tumors, as well as the commercialization of tumor early screening products and minimal residual disease (MRD) detection. ChosenMed strives to continue building tumor sample libraries and clinical databases of the Chinese population, providing clinical support for the development of new oncology drugs.